The University of Tennessee Research Foundation

Gtx Corporation

The Ohio State University

Oncternal Therapeutics, Inc.

Jianjun Chen

Duane Douglas Miller

Wei Li

James T Dalton

Chien-Ming Li

Sunjoo Ahn

Yan Lu

Zhao Wang

Jin Wang

Charles B Duke

Li Wei

The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.

Compounds for treatment of cancer

The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.

Compounds according to formula (I) are disclosed where Q is S, N, or O; X is optional, and can be O&#x2550;, S&#x2550;, &#x2550;N&#x2014;NH, &#x2550;N&#x2014;OH, or &#x2014;OH; Y is optional and can be &#x2014;N(H)&#x2014;, O, or Cto Chydrocarbon; and Rand Rare each independently substituted or unsubstituted single-, fused- or multiple-ring aryl or (hetero)cyclic ring systems. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.

Growing community of inventors

Knoxville, TN, United States of America

Jianjun Chen